Volume dana dhuwit perusahaan: Nautilus Biotechnology Inc (NAUT)

Tandha merek Nautilus Bio (NAUT)

Cash dynamics at Nautilus Biotechnology (NAUT) correlate with the company's plans to monetize its protein analysis system for the creation of personalized therapies. The current level of this metric stands at 0.09, supporting the development of the AI ecosystem and long-term B2B contracts with research centers. However, intense competition in the proteomics field and the expansion of DNA sequencing behemoths are forcing the company to strictly control its liquid reserves.

NAUT - Sisa dhuwit perusahaan nautilus.bio ing rentang 04.07.2022 - 21.11.2026

Ringkesan rincian data analitis nautilus.bio (NAUT)

Analisis umum perusahaan:NAUT Nautilus Bio
Produk mawa merek Nautilus Biotechnology

For Nautilus Biotechnology (NAUT), which is developing a complex proteomic platform, access to liquidity remains a critical survival factor until the company reaches the break-even point. An analysis of the cash reserve allows for an assessment of the deposit volume that either generates interest income or covers operating losses, determining the financial stability of this high-risk biotech asset amid fierce competition and high interest rates.

Pesaing Nautilus Biotechnology (NAUT)

Volume dana dhuwit perusahaan TEM|QGEN - Cadangan dhuwit perusahaan|ionispharma.com - Dhuwit awis perusahaan|Sisa dhuwit perusahaan RGEN|Avidity Corp - Volume dana dhuwit perusahaan|CRISPR Therapeutics Corp - Gunggung dana dhuwit perusahaan|GeneDx Holdings (WGS) - Dana dhuwit perusahaan|Ultragenyx Pharmaceutical (RARE) - Volume dana dhuwit perusahaan|Dhuwit awis perusahaan BEAM|Sarepta (SRPT) - Aset likuid perusahaan|Dana dhuwit perusahaan Twist Bioscience Corp (TWST)|10x - Dhuwit awis lan setara dhuwit awis perusahaan|Volume dana dhuwit perusahaan NTLA (intelliatx.com)|Gunggung dana dhuwit perusahaan STOK (stoketherapeutics.com)|BioLife Solutions Inc - Volume dana dhuwit perusahaan|WVE (Wave Life Sciences Ltd) - Dhuwit awis lan setara dhuwit awis perusahaan|Maze Therapeutics Corp (MAZE) - Dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan SION|PRME (Prime Medicine Inc) - Volume dana dhuwit perusahaan|Taysha Gene Therapies (TSHA) - Aset likuid perusahaan|Dhuwit awis perusahaan QURE (uniqure.com)|Gunggung dana dhuwit perusahaan MGTX|Volume dana dhuwit perusahaan RGNX (regenxbio.com)|SLDB: Dhuwit awis lan setara dhuwit awis perusahaan|ocugen.com - Volume dana dhuwit perusahaan|PACB - Volume dana dhuwit perusahaan|BNTC: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan DSGN|Dana dhuwit perusahaan Rocket Pharmaceuticals|Dhuwit awis perusahaan 4DMT (FDMT)|Volume dana dhuwit perusahaan LXEO|Aset likuid perusahaan Korro Bio Inc.|Volume dana dhuwit perusahaan EDIT (Editas Medicine Inc)|SLN: Dhuwit awis lan setara dhuwit awis perusahaan|PRQR - Dana dhuwit perusahaan|Aset likuid perusahaan codexis.com CDXS|SGMO: Volume dana dhuwit perusahaan|MGX - Aset likuid perusahaan|DTIL (Precision BioSciences Inc.) - Volume dana dhuwit perusahaan|generationbio.com (GBIO) - Aset likuid perusahaan|Dana dhuwit perusahaan Boundless Bio Inc (BOLD)|Volume dana dhuwit perusahaan Exicure Inc. (XCUR)|Dana dhuwit perusahaan imunon.com IMNN|Volume dana dhuwit perusahaan Phio Pharmaceuticals PHIO|Mustang Bio Inc - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan transcodetherapeutics.com|BNGO: Volume dana dhuwit perusahaan|Dhuwit awis lan setara dhuwit awis perusahaan APDN|BLUE (bluebirdbio.com) - Volume dana dhuwit perusahaan|Cadangan dhuwit perusahaan ImmunoPrecise Antibodies IPA|Dhuwit awis perusahaan OMGA (omegatherapeutics.com)|Volume dana dhuwit perusahaan Singular Genomics Systems, Inc. (OMIC)|Volume dana dhuwit perusahaan RGLS (Regulus Therapeutics, Inc.)|Volume dana dhuwit perusahaan Syros SYRS|Telesis Bio, Inc. - Volume dana dhuwit perusahaan|TRACON Pharmaceuticals (TCON) - Dhuwit awis perusahaan|UBX: Volume dana dhuwit perusahaan